Rea N, Bove F, Gentile A, Parmeggiani U
Institute of General Surgery, Medical and Surgical School, 2nd University of Naples.
Minerva Med. 1997 Nov;88(11):479-87.
We studied a group of 36 fertile women affected with moderate-to-severe cyclical mastalgia (mean age: 26.0 years) showing a normal menstrual history and normal basal levels of circulating hormones, including prolactin (PRL), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), progesterone (P), testosterone (T), dehydroepiandrosterone sulphate (delta HEAs), androstenedione (A). Using serial measurements of PRL plasma levels after an intravenous injection of thyrotropin-releasing hormone (TRH), (TRH test), patients were divided in two groups: 19 patients with abnormal PRL response to TRH and the remaining 17 with normal response.
Bromocriptine treatment, 2.5 mg b.i.d. for 3-6 months, was effective in 73.6% of patients with abnormal TRH test and in 23.5% of patients with normal TRH test: the difference was statistically significant. On the other hand, 76.9% of patients with either normal TRH test or resistant to bromocriptine therapy had a favourable response to percutaneous progesterone and systemic non-steroidal antiinflammatory drugs (NSAIDs).
These results seem to confirm the hypothesis that PRL response to TRH could be used to identify patients affected with cyclical mastalgia that are likely to benefit by bromocriptine treatment.
我们研究了一组36名患有中度至重度周期性乳腺疼痛的育龄妇女（平均年龄：26.0岁），她们月经史正常，循环激素基础水平正常，包括催乳素（PRL）、促黄体生成素（LH）、促卵泡激素（FSH）、雌二醇（E2）、孕酮（P）、睾酮（T）、硫酸脱氢表雄酮（δHEAs）、雄烯二酮（A）。通过静脉注射促甲状腺激素释放激素（TRH）后连续测量PRL血浆水平（TRH试验），将患者分为两组：19名对TRH的PRL反应异常的患者和其余17名反应正常的患者。
溴隐亭治疗，2.5mg，每日两次，持续3 - 6个月，在TRH试验异常的患者中有73.6%有效，在TRH试验正常的患者中有23.5%有效：差异具有统计学意义。另一方面，TRH试验正常或对溴隐亭治疗耐药的患者中有76.9%对经皮孕酮和全身性非甾体抗炎药（NSAIDs）有良好反应。
这些结果似乎证实了以下假设，即对TRH的PRL反应可用于识别可能从溴隐亭治疗中获益的周期性乳腺疼痛患者。
